Genprex, Inc. (NASDAQ:GNPX) Short Interest Down 37.6% in December

Genprex, Inc. (NASDAQ:GNPX) saw a significant decrease in short interest in December. As of December 31st, there was short interest totalling 396,100 shares, a decrease of 37.6% from the December 15th total of 634,600 shares. Based on an average daily volume of 9,330,000 shares, the short-interest ratio is currently 0.0 days. Approximately 4.8% of the shares of the stock are short sold.

Genprex Stock Performance

Shares of NASDAQ GNPX remained flat at $0.70 during midday trading on Thursday. The stock had a trading volume of 169,713 shares, compared to its average volume of 449,371. Genprex has a one year low of $0.28 and a one year high of $13.00. The stock has a fifty day simple moving average of $1.05 and a 200-day simple moving average of $1.13.

Institutional Trading of Genprex

An institutional investor recently raised its position in Genprex stock. Armistice Capital LLC boosted its position in shares of Genprex, Inc. (NASDAQ:GNPX) by 122.7% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 218,000 shares of the company’s stock after purchasing an additional 120,132 shares during the quarter. Armistice Capital LLC owned 10.39% of Genprex worth $411,000 as of its most recent SEC filing. 14.05% of the stock is owned by institutional investors and hedge funds.

About Genprex

Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.